Nakamura Kenichi, Koide Tetsuya, Higashiguchi Takahiko, Matsuo Kazuhiro, Endo Tomoyoshi, Kikuchi Kenji, Morohara Koji, Katsuno Hidetoshi, Uyama Ichiro, Suda Koichi, Morise Zenichi
Department of Surgery, Fujita Health University Okazaki Medical Center, 1 Gotanda, Harisaki-cho, Okazaki 444-0827, Aichi, Japan.
Department of Surgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, Toyoake 470-1192, Aichi, Japan.
J Clin Med. 2024 Dec 21;13(24):7819. doi: 10.3390/jcm13247819.
In Japan, the hinotori™ surgical robot system (Medicaroid Corporation, Kobe, Japan) was approved for gastrointestinal surgeries in October 2022. This report details our initial experience performing liver resection using the hinotori™ system. Ten patients, who were assessed as cases that would benefit from the robot-assisted procedure, underwent liver resections using the hinotori™ system at Fujita Health University, Okazaki Medical Center, between August 2023 and October 2024. The backgrounds (patient, tumor, and liver function conditions, along with types of liver resections and previous surgical procedures) and short-term outcomes (operation time, blood loss, postoperative complications, open conversion, length of hospital stay, and mortality) of the cases were evaluated. Eight cases of partial liver resection, one extended left medial sectionectomy, and one left hemi-hepatectomy were performed. Six cases of hepatocellular carcinomas, three cases of liver metastases, and one case of hepatolithiasis were included. There were seven male and three female patients with a median age of 70 years. Three physical status class III and seven class II patients were included. The median body mass index was 24. Five patients had previous upper abdominal surgical histories and five patients had liver cirrhosis. The median operation time was 419.5 min, and the median intraoperative blood loss was 276 mL. An open conversion in one hepatocellular carcinoma case was carried out due to bleeding from collateral vessels in the round ligament. The median length of hospital stay was 7.5 days. A grade IIIa complication (delayed bile leakage) was developed in one case. All patients with tumors underwent R0 resection. There were no cases of mortality. Liver resection using the hinotori™ system was feasibly performed. This study reports the first global use of the hinotori™ system for liver resection.
在日本,hinotori™手术机器人系统(日本神户的Medicaroid Corporation公司)于2022年10月被批准用于胃肠道手术。本报告详细介绍了我们使用hinotori™系统进行肝切除术的初步经验。2023年8月至2024年10月期间,10名被评估为将从机器人辅助手术中受益的患者在藤田保健大学冈崎医疗中心使用hinotori™系统接受了肝切除术。对这些病例的背景(患者、肿瘤和肝功能状况,以及肝切除类型和既往手术史)和短期结果(手术时间、失血量、术后并发症、中转开腹、住院时间和死亡率)进行了评估。共进行了8例部分肝切除术、1例扩大左内侧段切除术和1例左半肝切除术。其中包括6例肝细胞癌、3例肝转移瘤和1例肝内胆管结石。患者中男性7例,女性3例,中位年龄为70岁。包括3例身体状况为Ⅲ级和7例Ⅱ级的患者。中位体重指数为24。5例患者有上腹部手术史,5例患者有肝硬化。中位手术时间为419.5分钟,中位术中失血量为276毫升。1例肝细胞癌病例因圆韧带侧支血管出血而中转开腹。中位住院时间为7.5天。1例发生Ⅲa级并发症(延迟性胆漏)。所有肿瘤患者均接受了R0切除。无死亡病例。使用hinotori™系统进行肝切除术是可行的。本研究报告了hinotori™系统在全球首次用于肝切除术。